Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment

Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment

BACKGROUND Despite its recognised toxicity, antimonial therapy continues to be the first-line drug for cutaneous leishmaniasis (CL) treatment. Intralesional administration of meglumine antimoniate (MA) represents an alternative that could reduce the systemic absorption of the drug and its side effec...

Full description

Bibliographic Details
Main Authors:	Rosiana Estéfane da Silva, Janaína de Pina Carvalho, Dario Brock Ramalho, Maria Camilo Ribeiro De Senna, Hugo Silva Assis Moreira, Ana Rabello, Erika Cota, Gláucia Cota
Format:	Article
Language:	English
Published:	Fundação Oswaldo Cruz (FIOCRUZ)
Series:	Memorias do Instituto Oswaldo Cruz
Subjects:	cutaneous leishmaniasis therapy meglumine antimoniate intralesional infiltration validation
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762018000200071&lng=en&tlng=en

Similar Items

Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre
by: Rosiana Estéfane da Silva, et al.
Published: (2016-08-01)

Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
by: Dario Brock Ramalho, et al.
Published: (2018-06-01)

Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities
by: Maria Inês Fernandes Pimentel, et al.

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
by: Erica de Camargo Ferreira e Vasconcellos, et al.
Published: (2014-07-01)

Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis
by: Maria Cristina de Oliveira Duque, et al.

Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series
by: Margarita Arboleda, et al.
Published: (2019-05-01)

Comparison of Intralesional Meglumine Antimoniate Plus Oral Allopurinol with Intralesional Meglumine Antimoniate Alone for the Treatment of Cutaneous Leishmaniasis- A Prospective Study
by: Nida Qayyum, et al.
Published: (2024-05-01)

Mucosal leishmaniasis: the experience of a Brazilian referral center
by: Mariana Junqueira Pedras, et al.

Treatment of cutaneous leishmaniasis with combination of allopurinol and low dose of meglumine antimoniate
by: A Momeni, et al.
Published: (2001-03-01)

The Additive Effect of Topical Ciprofloxacin 2% on Intralesional Glucantime Injection in Treatment of Cutaneous Leishmaniasis
by: Mohamadjavad Yazdanpanah, et al.
Published: (2020-06-01)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
by: Deninson Alejandro Vargas, et al.
Published: (2019-06-01)

Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis
by: Michal Solomon, et al.
Published: (2024-04-01)

Pharmacokinetics of neutron-irradiated meglumine antimoniate in Leishmania amazonensis-infected BALB/c mice
by: Samanta Etel Treiger Borborema, et al.
Published: (2019-03-01)

PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
by: Marcelo Rosandiski LYRA, et al.

Warning against increasing cases of cutaneous leishmaniasis and unavailability of meglumine in Pakistan
by: Sadia Iram, et al.
Published: (2023-12-01)

Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia
by: Ernesto Rojas Cabrera, et al.
Published: (2022-10-01)

The Efficacy of Intralesional Meglumine Antimoniate (Glucantime) versus a Combination of Topical Trichloroacetic Acid 50% and Local Heat Therapy by Non-Ablative Radiofrequency on Cutaneous Leishmaniasis Lesions
by: Mohammad Ali Nilforoushzadeh, et al.
Published: (2011-12-01)

Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate
by: Armando de Oliveira Schubach, et al.
Published: (2005-05-01)

Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia
by: Maria del Mar Castro, et al.
Published: (2022-03-01)

Estimating direct costs of the treatment for mucosal leishmaniasis in Brazil
by: Janaína de Pina Carvalho, et al.
Published: (2021-01-01)

Pentavalent Antimonials: New Perspectives for Old Drugs
by: Raul R. Ribeiro, et al.
Published: (2009-06-01)

The Efficacy of Carbon Dioxide Laser in the Treatment of Chronic and Lupoid Cutaneous Leishmaniasis in Kerman City: A Randomized Clinical Trial
by: I Esfandiarpour, et al.
Published: (2014-07-01)

Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)
by: Lucia Regina Brahim, et al.

Treatment of Canine Leishmaniasis with Meglumine Antimoniate: A Clinical Study of Tolerability and Efficacy
by: Serena Digiaro, et al.
Published: (2024-08-01)

The Efficacy, Relapse and Failure in the Treatment of Anthroponotic Cutaneous Leishmaniosis with Intralesional Glucantime Along with Cryotherapy
by: Mehran Karvar, et al.
Published: (2016-03-01)

Poor response to azithromycin in cutaneous leishmaniasis leading to a premature interruption of a multicentric phase III clinical trial in Brazil
by: Antonio Toledo Junior, et al.
Published: (2014-12-01)

Hypersensitivity eosinophilic myocarditis possibly triggered by meglumine antimoniate
by: Sergio A. Bolivar-Lozano, et al.
Published: (2024-03-01)

A Promising Cutaneous Leishmaniasis Treatment with a Nanoemulsion-Based Cream with a Generic Pentavalent Antimony (Ulamina) as the Active Ingredient
by: Johnny Bullón, et al.
Published: (2021-12-01)

Pentavalent Antimony Associated with G-CSF in the Treatment of Cutaneous Leishmaniasis Caused by <i>Leishmania (Viannia) braziliensis</i>
by: Carvel Suprien, et al.
Published: (2024-04-01)

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis
by: Diana Berenguer, et al.
Published: (2019-11-01)

In vitro and in vivo activity of meglumine antimoniate produced at Farmanguinhos-Fiocruz, Brazil, against Leishmania (Leishmania) amazonensis, L (L.) chagasi and L (Viannia) braziliensis
by: Eliane de Morais-Teixeira, et al.
Published: (2008-06-01)

High and low doses of antimony (Sb v) in American cutaneous leishmaniasis: a five years follow-up study of 15 patients
by: MP Oliveira-Neto, et al.
Published: (1996-04-01)

Comparison of intralesional two percent zinc sulfate and glucantime injection in treatment of acute cutaneous leishmaniasis
by: Masoud Maleki, et al.
Published: (2012-01-01)

Comparison between topical treatment with thioxolone , benzoxonium chloride tincture and intralesional injection of meglumine antymoniate on cutaneous leishmaniasis
by: M.H Daei-Parizi, et al.
Published: (1995-12-01)

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE
by: Cláudia Maria Valete-Rosalino, et al.
Published: (2014-09-01)

Preparation and Evaluation of Clinical Effects of Glucantime Gel Mask
by: Sayed Abolfazl Mostafavi, et al.
Published: (2013-06-01)

Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity
by: Samanta Etel Treiger Borborema, et al.
Published: (2016-04-01)

FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
by: Madelon Novato Ribeiro, et al.
Published: (2014-07-01)

Efficacy of the treatment using a microemulsion loaded with epoxy-α-lapachone in combination with meglumine antimoniate against murine infection by Leishmania (Leishmania) amazonensis
by: Juliana Figueiredo Peixoto, et al.
Published: (2024-04-01)

An intermittent schedule is better than continuous regimen of antimonial therapy for cutaneous leishmaniasis in the municipality of Rio de Janeiro, Brazil
by: Rilza Beatriz G. de Azeredo-Coutinho, et al.
Published: (2002-10-01)